Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ABBV-011 + Budigalimab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ABBV-011 | SC-011|ABBV011|ABBV 011|SC011|SC 011 | ABBV-011 (SC-011) is an antibody-drug conjugate (ADC) targeting SEZ6, which potentially inhibits tumor growth (PMID: 35642431). | ||
| Budigalimab | ABBV181|ABBV 181|ABBV-181 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | Budigalimab is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32770720). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03639194 | Phase I | ABBV-011 + Budigalimab ABBV-011 | A Study of SC-011 Alone and in Combination With ABBV-181 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | Completed | USA | 3 |